InvestorsHub Logo
Followers 11
Posts 142
Boards Moderated 0
Alias Born 11/10/2022

Re: soma2022 post# 9044

Monday, 01/06/2025 1:36:02 PM

Monday, January 06, 2025 1:36:02 PM

Post# of 9090
I feel that Bill Meury (Chair of Crown and Hildred Capital Senior Adviser) will not want over 1 year of hard work and expense to slip away at just a $0.50/share higher price = $52M.

Background of Bill Meury: https://www.hildred.com/team/bill-meury
Allergan's Chief Commercial Officer from 2015 to 2020. Bill was with Actavis in 2014 and was instrumental along with Brent Saunders in blocking Valeant's hostile takeover of Allergan. Actavis then took on the Allergan name and was eventually acquired by Abbvie in 2019.
https://www.reuters.com/article/business/allergan-agrees-to-66-billion-actavis-offer-valeant-walks-idUSKCN0J00W7/

There are indications that Allergan looked at potentially acquiring Revance some 8 to 10 years ago. If these rumors are true, then Bill Meury would have been actively involved in those discussions. If this is the case, then Bill has been patiently stalking Revance waiting for an opportunity like this for almost 10 years.

There is a reasonably strong possibility that Crown will increase their offer price.
Volume: -
Day Range:
Bid: 3.84
Ask: 3.10
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RVNC News